TCGA-D8-A1XY-01A-11R-A14M-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 17
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- INTERFERON_ALPHA_RESPONSE+0.350
- UV_RESPONSE_DN+0.340
- ANDROGEN_RESPONSE+0.250
- TGF_BETA_SIGNALING+0.250
- ESTROGEN_RESPONSE_EARLY+0.240
- CHOLESTEROL_HOMEOSTASIS+0.230
- ANGIOGENESIS+0.210
- HEME_METABOLISM+0.180
Top 10 suppressed
- E2F_TARGETS-0.480
- G2M_CHECKPOINT-0.450
- ALLOGRAFT_REJECTION-0.360
- MYC_TARGETS_V1-0.330
- IL6_JAK_STAT3_SIGNALING-0.280
- DNA_REPAIR-0.220
- MYC_TARGETS_V2-0.220
- KRAS_SIGNALING_DN-0.210
- SPERMATOGENESIS-0.190
- MITOTIC_SPINDLE-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20030031.LumA | — | A | 0.823 |
| 2 | TCGA-AN-A0XP-01A-11R-A109-07 | — | B | 0.781 |
| 3 | SRR4296096 | — | cohortA1 | 0.774 |
| 4 | TCGA-E9-A1RI-01A-11R-A169-07 | — | A | 0.770 |
| 5 | MDT-AP-3286 | Med | Medulloblastoma | 0.751 |
| 6 | TCGA-A8-A07G-01A-11R-A034-07 | — | A | 0.727 |
| 7 | TCGA-A1-A0SD-01A-11R-A115-07 | — | A | 0.716 |
| 8 | TCGA-FD-A5BZ-01A-11R-A28M-07 | — | — | 0.713 |
| 9 | TCGA-D8-A1XU-01A-11R-A14M-07 | — | A | 0.705 |
| 10 | TCGA-FD-A3SQ-01A-21R-A22U-07 | — | — | 0.700 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.170 | Idelalisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |